Risk factors for early-phase clozapine discontinuation: A nested case-control study

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Treatment-resistant schizophrenia (TRS) requires safe and effective therapeutic options.
• Clozapine is a critical medication for managing TRS, but its introduction can be challenging.
• Understanding early discontinuation risks is vital for optimizing clozapine therapy.

Purpose of the Study:

• To identify risk factors associated with early clozapine discontinuation in patients with TRS.
• To evaluate the safety and efficacy of clozapine introduction in a Japanese cohort.

Main Methods:

• A nested case-control study was conducted across 14 psychiatric hospitals in Japan.
• Data from 228 TRS patients were collected up to 12 weeks pre- and post-clozapine initiation.
• Risk factors analyzed included demographics, prior/concomitant medications, and clinical assessments.

Main Results:

• Clozapine was continued in 93.4% of patients within 12 weeks, with 14.9% showing symptom improvement.
• Smoking history and prior antipsychotic treatment <1200 mg chlorpromazine equivalents increased discontinuation risk.
• Eosinophilia, linked to concomitant valproate, was the primary discontinuation reason (20%).

Conclusions:

• Clozapine is effective for TRS patients in Japan, particularly those previously on higher antipsychotic doses.
• Clinicians must monitor for eosinophilia when initiating clozapine with valproate.
• Early identification of risk factors can improve clozapine treatment outcomes.